Citations

Clear

11 citation(s) found for "Chen, Kai".

PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Tzeng, Sheue‐Fen , Yu, Yi-Ru , Park, Jaeoh , Renesse, Janusz von , Hsiao, Huey-Wen , Hsu, Chen-Hsuan , Garnica, Josep , Chen, Jintian , Chiu, Lu-Ting , Santol, Jonas , Chen, Tse-Yu , Chung, Pei-Han , Meng, Zhen , Lin, Yun-Han, Tsai, Chin‐Hsien , von Renesse, Janusz , Kandalaft, Lana E , Starlinger, Patrick , Hsieh, Rodney Cheng-En , Yu, Ming-Chin , Hsiao, Pei-Wen , Carmona, Santiago J , Chen, Hung-Kai , Meng, Zhen , Lin, Yun-Han , Zhou, Jingying , Tsai, Chin-Hsien , Ho, Ping-Chih , Santol, Jonas , Starlinger, Patrick , Hsieh, Cheng‐En

Mayo Clinic

Cancer Discovery | April 28, 2025 | Volume: 15 | Issue: 8 | Pages: 1676-1696

10.1158/2159-8290.cd-24-1409 | PMID 40294022 Get It

Abstract Tumor cells develop various strategies to evade immune surveillance, one of which involves altering the metabolic state of the tumor microenvironment. In response to metabolic stress in the tumor microenvironment, several tumor-infiltrating immune subsets upregulate CD36 to take up lipids. This leads to impaired antitumor immunity, as intratumoral regulatory T cells exhibit increased survival and suppressive activity, whereas CD8+ T cells become more susceptible to ferroptosis and exhaustion. In this study, we develop a humanized anti-CD36 IgG4 antibody, PLT012, against the lipid-binding domain of CD36 with excellent safety and favorable pharmacokinetic features in mice and cynomolgus monkeys. PLT012 alone or in combination with PD-L1 blockade or standard-of-care immunotherapy results in robust antitumor immunity in both immunotherapy-sensitive and -resistant hepatocellular carcinomas (HCC). Notably, PLT012 also reprograms the immune landscape of human HCC ex vivo. Our findings provide proof-of-concept evidence that PLT012 reprograms antitumor immunity in HCC, positioning it as a first-in-class immunotherapy targeting CD36. Significance: Despite the success of cancer immunotherapies, like immune checkpoint inhibitors, many patients still fail to demonstrate significant responses because of metabolic constraints in tumors. PLT012 rejuvenates antitumor immunity by targeting metabolic pathways to reprogram the immune landscape of liver cancer and liver metastasis, with potential to influence future HCC immunotherapy.
APOE genotype modifies benefits of calorie restriction against aging
Chen, Yixing , Ren, Yingxue , Ikezu, Tadafumi C. , Pan, Meixia , Kashyap, Sonu , Bueser, Katrina Rae , Wetmore, Allison M, Kurti, Aishe, Meneses, Axel , Owens, Jada A., Chini, Eduardo N. , Chen, Jun, Qiao, Wenhui , Johnson, Stephen A. , Li, Fuyao , Chen, Kai , Owens, Jada A., Chen, Jun, Han, Xianlin , Bu, Guojun , Zhao, Na

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.085702 Get It

AbstractBackgroundThe efficacy of Calorie Restriction (CR) in enhancing cognition, promoting healthy aging, and extending lifespan is well‐established. Yet, it remains unclear whether the apolipoprotein E (APOE) genotype, a known modifier for aging and age‐related disorders, influences the beneficial effects of CR in countering aging.MethodsTo investigate this question, we utilized humanized APOE mouse models, which express APOE2, APOE3, or APOE4 alleles systematically (refer to as E2, E3, and E4 mice). These mice were subjected to either ad libitum (AL) feeding or 30% CR feeding, starting from 12 months and continuing up to 20 months of age (N = 11‐20/ genotype /group, mixed sex). We monitored energy expenditure using the Comprehensive Laboratory Animal Monitoring System (CLAMS). Additionally, we evaluated anxiety levels and memory capabilities through various behavioral tests. Finally, we collected brain, blood, and feces samples for transcriptomic, lipidomic, and microbiomic analyses.ResultsCLAMS measurements showed that CR significantly decreased the metabolic rate in E3 and E4 mice, but not E2 mice, during the non‐feeding period of the CR group, compared to the AL group. Furthermore, CR reduced anxiety and enhanced associative memory in E3 and E4 mice relative to the AL group. Brain transcriptomics revealed that CR upregulated the cholesterol synthesis pathway, potentially improving myelination‐related pathways in E3 and E4 mice. This finding was further validated by the increased staining intensity of myelin basic protein (MBP) observed in E3 and E4 mice from an independent cohort. In contrast, these effects were not pronounced in E2 mice. Additionally, while CR’s impact on the brain lipid profile was minor across all APOE genotypes, it significantly altered blood lipid profile of E2 mice, with minimal changes observed in E3 and E4 mice. Finally, in microbiomics, CR led to notable changes in the abundance of Bifidobacterium species in E3 and E4 mice and Lactobacillus species in E2 mice.ConclusionsOur study highlights the role of APOE genotypes in modulating the diverse effects of CR on cognition, brain transcriptomics, lipid metabolism, and the microbiome, providing a crucial foundation for considering APOE genotypes in developing prevention strategies for aging and age‐related disorders.
High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML
Litzow, Mark R. , Chen, George , Nath, Rajneesh , Seropian, Stuart , Choe, Hannah , Abboud, Camille N. , Koshy, Nebu , Tomlinson, Ben K. , Abhyankar, Sunil , Foran, James M. , Abedin, Sameem , Al‐Kadhimi, Zaid , Orozco, Johnnie J. , Jamieson, Katarzyna , Schuster, Michael W., Law, Arjun , Mayer, Sebastian , Leung, Eugene , Chen, Ming-Kai , Natwa, Mona, Spross, Jennifer , Li, Kate L, Nagl, Norman G., Haeuber, Elaina, Vusirikala, Madhuri , Nahar, Akash, Pagel, John M. , Desai, Avinash, Brodin, P., Stiff, Patrick J. , Abedin, Sameem , Gyurkocza, Boglarka , Kebriaei, Partow , Sabloff, Mitchell , Magalhaes‐Silverman, Margarida , Besien, Koen van , Lazarus, Hillard M. , Leung, Eugene , Sandmaier, Brenda M , Giralt, Sergio , Desai, Avinash, Wahl, Richard L. , Pandit-Taskar, Neeta D.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 3529-3529

10.1182/blood-2023-189040 Get It

Background: Most older patients (pts) with relapsed or refractory (R/R) AML cannot tolerate intensive treatment and are not eligible for curative allogeneic hematopoietic cell transplant (alloHCT). 131I-apamistamab, an anti-CD45 radioimmunoconjugate, delivers high dose targeted radiation to hematopoietic cells, allowing for myeloablation and eradication of leukemic cells. 131I-apamistamab led induction and conditioning can provide these pts with access to alloHCT. Methods: SIERRA (NCT02665065) was a multi-center, randomized, controlled phase 3 study comparing the efficacy of 131I-apamistamab led induction and conditioning versus physician's choice of conventional care (CC) in pts ≥55 years of age with active, R/R AML. Pts were randomized (1:1, n=153) to CC or 131I-apamistamab with fludarabine and total body irradiation (2 Gy) followed by alloHCT. Primary endpoint was durable complete remission (dCR), defined as CR ≥6 mos with or without platelet recovery (CRp). Pts not achieving CR in CC could crossover (CO) to receive 131I-apamistamab. Treatment with 131I-apamistamab was prescribed as an individualized dose for each pt following a dosimetric infusion and biodistribution analysis, with the prescribed activity of 131I set to deliver a maximum estimated radiation dose to the liver as the dose limiting organ of 24 Gy (determined as the maximum tolerable dose (MTD)) in earlier studies), thereby providing the highest dose to the diseased bone marrow and circulating leukemic cells without exceeding individual organ radiation dose tolerances. Here, we performed an analysis to determine whether a radiation dose-response relationship could be established based on either 1) administered radiation dose to liver and the rate of achieving the primary endpoint of dCR (with 95% binomial confidence intervals) or 2) dCR rate and the ratio of bone marrow/liver absorbed radiation dose as an indicator of favorable biodistribution between target/risk organ. Results: All pts receiving the therapeutic dose of 131I-apamistamab (n=66) were able to receive an alloHCT, and the primary endpoint (dCR) was achieved in 13 pts receiving 131I-apamistamab vs 0 pts in CC (p<0.0001). The median absorbed liver dose was 21.6 Gy (IQR: 21.0 - 22.8 Gy), median absorbed dose to bone marrow was 16.0 Gy (IQR: 11.5 - 22.3 Gy), and median ratio between marrow/liver dose was 0.79 (IQR: 0.52 - 1.02). Table 1 shows the distribution and rate of dCR for pts who received above or below 22 Gy administered dose to liver (24 Gy to liver was the established MTD from earlier studies, in which doses were escalated in 2 Gy increment and thus, 22 Gy represented MTD-1), and for pts stratified by marrow/liver dose ratio (higher ratio representing more favorable biodistribution). Pts with ≤22 Gy liver dose had a dCR rate of 13.5% vs. 27.6% for pts with >22 Gy liver dose, and pts with <median dose to bone marrow had a dCR rate of 12.1% vs. 27.3% for pts with ≥median estimated marrow dose. Importantly, pts with increasingly favorable biodistribution had nominally higher dCR rates of 10.0%, 20.0% and 26.9% for a marrow/liver ratio <0.6, 0.6-0.9 and >0.9, respectively, as illustrated in Figure 1. Taken together this demonstrates a radiation dose-response for the primary endpoint in this study. Overall, safety was similar across doses to the liver. Conclusion: 131I-apamistamab led induction and conditioning followed by alloHCT resulted in statistically significant improvement in dCR at 6 mos vs conventional care. A dose-response was demonstrated for pts receiving 131I-apamistamab with those receiving a liver dose closer to the MTD of 24 Gy having about twice the dCR rate compared to pts 22 Gy (MTD-1) or less. We also found pts with higher marrow/liver ratio experienced considerably higher rates of dCR which highlights the importance of maximizing the dose to target tissues, within the limits of established risk organ dose tolerances.
Spaceflight alters insulin and estrogen signaling pathways
Tabetah, Marshall , Karim, Rashid , Zaksas, Victoria , I, Anu, Muratani, Masafumi , Tasoula, Alexia , Singh, Ruth Subhash, Chen, Yen-Kai, Povero, Davide , Klotz, Rémi , Mason, Christopher E. , Clair, Riley St, Karouia, Fathi , Mathyk, Begüm Aydoğan , Kim, JangKeun , Chen, Yen-Kai, Overbey, Eliah G. , Park, Jiwoon , Borg, Joseph , Yu, Min A , Young, Steven L. , Mason, Christopher E , Szewczyk, Nathaniel J. , Clair, Riley M. St. , Beheshti, Afshin

Mayo Clinic

No container title available | January 4, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2362750/v1 Get It

Abstract Organismal adaptations to spaceflight have been characterized at the molecular level in model organisms, including Drosophila and C. elegans. Here we extend molecular work to energy metabolism and sex hormone signaling in mice and humans. We found spaceflight-induced changes in insulin and estrogen signaling in rodents and humans. Murine changes were most prominent in the liver, where we observed inhibition of insulin and estrogen receptor signaling with concomitant hepatic insulin resistance and steatosis. Based on the metabolic demand, metabolic pathways mediated by insulin and estrogen vary among muscles, specifically between the soleus and extensor digitorum longus. In humans, spaceflight induced changes in insulin and estrogen related genes and pathways. Pathway analysis demonstrated spaceflight-induced changes in insulin resistance, estrogen signaling, stress response, and viral infection. These data strongly suggest the need for further research on the metabolic and reproductive endocrinologic effects of space travel, if we are to become a successful interplanetary species
APOE2 Exacerbates TDP‐43 Related Toxicity in the Absence of Alzheimer Pathology
Meneses, Axel , Li, Zonghua , O’Leary, Justin , Li, Fuyao , Nakamura, M. , Kurti, Aishe, Heckman, Michael G. , White, Launia J. , Xie, Manling , Chen, Yixing , Finch, NiCole A., Lim, Melina J., Delenclos, Marion , DeTure, Michael , Martin, Nicholas B. , Ikezu, Tadafumi C. , Blitterswijk, Marka van , Wu, Long‐Jun , McLean, Pamela J. , Rademakers, Rosa , Ross, Owen A. , Bu, Guojun , Zhao, Na , Meneses, Axel D , Li, Zonghua , O'Leary, Justin, Li, Fuyao , Chen, Kai , Murakami, Aya , Qiao, Wenhui , Heckman, Michael G , White, Launia, DeTure, Michael A, Linares, Cynthia , van Blitterswijk, Marka M, Ross, Owen A , Dickson, Dennis W , Zhao, Na , van Blitterswijk, Marka , Wu, Long-Jun , Bu, Guojun , Chen, Yixing , Xie, Manling , McLean, Pamela J , Koga, Shunsuke , Chen, Kai , Dickson, Dennis W.

Mayo Clinic

Annals of Neurology | December 22, 2022 | Volume: 93 | Issue: 4 | Pages: 830-843

10.1002/ana.26580 | PMID 36546684 Get It

ObjectiveRecent evidence supports a link between increased TDP‐43 burden and the presence of an APOE4 gene allele in Alzheimer's disease (AD); however, it is difficult to conclude the direct effect of APOE on TDP‐43 pathology due to the presence of mixed AD pathologies. The goal of this study is to address how APOE isoforms impact TDP‐43 pathology and related neurodegeneration in the absence of typical AD pathologies.MethodsWe overexpressed human TDP‐43 via viral transduction in humanized APOE2, APOE3, APOE4 mice, and murine Apoe‐knockout (Apoe‐KO) mice. Behavior tests were performed across ages. Animals were harvested at 11 months of age and TDP‐43 overexpression‐related neurodegeneration and gliosis were assessed. To further address the human relevance, we analyzed the association of APOE with TDP‐43 pathology in 160 postmortem brains from autopsy‐confirmed amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with motor neuron disease (FTLD‐MND) in the Mayo Clinic Brain Bank.ResultsWe found that TDP‐43 overexpression induced motor function deficits, neuronal loss, and gliosis in the motor cortex, especially in APOE2 mice, with much milder or absent effects in APOE3, APOE4, or Apoe‐KO mice. In the motor cortex of the ALS and FTLD‐MND postmortem human brains, we found that the APOE2 allele was associated with more severe TDP‐43‐positive dystrophic neurites.InterpretationOur data suggest a genotype‐specific effect of APOE on TDP‐43 proteinopathy and neurodegeneration in the absence of AD pathology, with the strongest association seen with APOE2. ANN NEUROL 2023;93:830–843
Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia
Zhao, Na , Qiao, Wenhui , Li, Fuyao , Ren, Yingxue , Zheng, Jiaying , Martens, Yuka A. , Wang, Xusheng , Li, Ling , Liu, Chia‐Chen , Chen, Kai , Zhu, Yiyang , Ikezu, Tadafumi C. , Li, Zonghua , Meneses, Axel , Jin, Yunjung , Chen, Yixing , Sonustun, Berkiye , Job, Lucy , Smith, Madeleine L. , Xie, Manling , Liu, Yong , Umpierre, Anthony D. , Haruwaka, Koichiro , Quicksall, Zachary , Störz, Peter , Asmann, Yan W. , Wu, Long‐Jun , Bu, Guojun , Meneses, Axel D , Knight, Joshua A , Chen, Yixing , Bastea, Ligia , Linares, Cynthia , Sonustun, Berkiye , Job, Lucy , Smith, Madeleine L , Xie, Manling , Liu, Yong U , Umpierre, Anthony D , Haruwaka, Koichiro , Quicksall, Zachary S , Storz, Peter , Asmann, Yan W , Wu, Long-Jun , Bu, Guojun , Liu, Chia-Chen , Zhao, Na , Li, Fuyao , Zheng, Jiaying , Knight, Joshua A. , Bastea, Ligia I.

Mayo Clinic

Journal of Experimental Medicine | September 15, 2022 | Volume: 219 | Issue: 12 | Pages: No page available

10.1084/jem.20212479 | PMID 36107206 Get It

TREM2 is exclusively expressed by microglia in the brain and is strongly linked to the risk for Alzheimer’s disease (AD). As microglial responses modulated by TREM2 are central to AD pathogenesis, enhancing TREM2 signaling has been explored as an AD therapeutic strategy. However, the effective therapeutic window targeting TREM2 is unclear. Here, by using microglia-specific inducible mouse models overexpressing human wild-type TREM2 (TREM2-WT) or R47H risk variant (TREM2-R47H), we show that TREM2-WT expression reduces amyloid deposition and neuritic dystrophy only during the early amyloid seeding stage, whereas TREM2-R47H exacerbates amyloid burden during the middle amyloid rapid growth stage. Single-cell RNA sequencing reveals suppressed disease-associated microglia (DAM) signature and reduced DAM population upon TREM2-WT expression in the early stage, whereas upregulated antigen presentation pathway is detected with TREM2-R47H expression in the middle stage. Together, our findings highlight the dynamic effects of TREM2 in modulating AD pathogenesis and emphasize the beneficial effect of enhancing TREM2 function in the early stage of AD development.
­TREM2-H157Y Increases Soluble TREM2 Production and Reduces Amyloid Pathology
Qiao, Wenhui , Chen, Yixing , Martens, Yuka A. , Li, Fuyao , Aishe, Kurti I., Dacquel, Maxwell V., Fryer, John Denis , Chen, Kai , Li, Fuyao , Liu, Chia‐Chen , Knight, Joshua A. , Chen, Kai , Shue, Francis , Zhao, Na , Bu, Guojun

Mayo Clinic

No container title available | October 13, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-960300/v1 Get It

Abstract Background: The p.H157Y variant of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) has been reported to increase Alzheimer’s disease (AD) risk. This mutation in the extracellular domain of TREM2 localizes at the cleavage site and was shown to enhance shedding and impair phagocytosis in vitro by ectopic expression of TREM2-H157Y in HEK293 cells. However, the physiological and AD-related outcomes of TREM2 H157Y mutation in vivo remain unknown.Methods: We generated a novel Trem2 H157Y knock-in mouse model through CRISPR-Cas9 technology and investigated how Trem2 H157Y mutation impacts TREM2 proteolytic processing, synaptic function, and AD-related amyloid pathology by conducting biochemical assays, immunofluorescent staining, hippocampal electrophysiology, and in vivo micro-dialysis in awake, free-moving animals.Results: Consistent with previous in vitro findings, TREM2-H157Y increases the amount of soluble TREM2 (sTREM2) in the cortex and serum of mutant mice compared to the wild type controls. Interestingly, the Trem2 H157Y variant enhances synaptic plasticity without affecting microglial density and morphology. In the presence of amyloid pathology, TREM2-H157Y surprisingly accelerates Aβ clearance and reduces amyloid burden and microgliosis. Conclusion: Taken together, our findings support a beneficial effect of the Trem2 H157Y mutation in synaptic function and in mitigating amyloid pathology. Considering the genetic association of TREM2 p.H157Y with AD, we speculate TREM2-H157Y might increase AD risk through an amyloid-independent pathway, as such its effects on tauopathy and neurodegeneration merit further investigation.
Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD
Wingerchuk, Dean M. , Palace, Jacqueline , Levy, Michael , Kim, Jung Bin , Nakashima, Ichiro , Wang, Kai‐Chen , Miller, Larisa , Shang, Shulian, Sabatella, Guido, Yountz, Marcus, Pittock, Sean J. , Group, PREVENT Study, Sıva, Aksel , Tütüncü, Melih , Palace, Jacqueline , Pozzilli, Carlo , Clardy, Stacey , Hardy, Todd A. , Messina, Silvia , Totolyan, N. А. , Huda, Saif , Barnett, Michael , Sahagian, Gregory , Levy, Michael , Pittock, S J , Clardy, Stacey L , Nakashima, Ichiro , Siva, Aksel , Hardy, Todd A , Messina, Silvia , Palace, Jacqueline , Fujihara, Kazuo , Berthele, Achim , Oreja‐Guevara, Celia , Group, PREVENT Study, Barnett, Michael H , Pozzilli, Carlo

Mayo Clinic

Annals of Neurology | February 17, 2021 | Volume: 89 | Issue: 6 | Pages: 1088-1098

10.1002/ana.26049 | PMID 33586143 Get It

ObjectiveDuring PREVENT (NCT01892345), eculizumab significantly reduced relapse risk versus placebo in patients with aquaporin‐4 immunoglobulin G‐positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD). We report an interim analysis of PREVENT's ongoing open‐label extension (OLE; NCT02003144) evaluating eculizumab's long‐term safety and efficacy.MethodsPatients who completed PREVENT could enroll in the OLE to receive eculizumab (maintenance dose = 1,200 mg/2 weeks, after a blinded induction phase). Safety and efficacy data from PREVENT and its OLE (interim data cut, July 31, 2019) were combined for this analysis.ResultsAcross PREVENT and the OLE, 137 patients received eculizumab and were monitored for a median (range) of 133.3 weeks (5.1–276.9 weeks), for a combined total of 362.3 patient‐years (PY). Treatment‐related adverse event (AE) and serious adverse event (SAE) rates were 183.5 in 100 PY and 8.6 in 100 PY, respectively. Serious infection rates were 10.2 in 100 PY in eculizumab‐treated patients versus 15.1 in 100 PY in the PREVENT placebo group. No patient developed a meningococcal infection. At 192 weeks (3.7 years), 94.4% (95% confidence interval [CI], 88.6–97.3) of patients remained adjudicated relapse‐free. The adjudicated annualized relapse rate was 0.025 (95% CI = 0.013–0.048) in all eculizumab‐treated patients versus 0.350 (95% CI = 0.199–0.616) in the PREVENT placebo group. During the OLE, 37% of patients (44 of 119 patients) stopped or decreased background immunosuppressive therapy use.InterpretationThis analysis demonstrates that eculizumab's long‐term safety profile in NMOSD is consistent with its established profile across other indications. This analysis also demonstrated the sustained ability of long‐term eculizumab treatment to reduce relapse risk in patients with AQP4‐IgG+ NMOSD. ANN NEUROL 2021;89:1088–1098